Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Keri Wellington"'
Autor:
Susan J Keam, Keri Wellington
Publikováno v:
Drugs. 66:837-850
Bicalutamide (Casodex) is a competitive androgen receptor antagonist that inactivates androgen-regulated prostate cell growth and function, leading to cell apoptosis and inhibition of prostate cancer growth. It is administered orally as a once-daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::973145f5bad39724b0446084cc81ad5e
https://doi.org/10.2165/00003495-200666060-00007
https://doi.org/10.2165/00003495-200666060-00007
Autor:
Keri Wellington, Dean M Robinson
Publikováno v:
Drugs. 66:257-271
A low-dose sustained-release (SR) formulation of the thiazide-type diuretic indapamide, indapamide SR (Natrilix® SR), retains the antihypertensive activity of the immediate-release (IR) formulation, with a smoother pharmacokinetic profile. In well c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ebaed38f5db3d26b188683c4d949852
https://doi.org/10.2165/00003495-200666020-00011
https://doi.org/10.2165/00003495-200666020-00011
Autor:
Keri Wellington
Publikováno v:
Drugs. 65:1581-1592
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d93b819c7c21e8e019f79532701eb366
https://doi.org/10.2165/00003495-200565110-00013
https://doi.org/10.2165/00003495-200565110-00013
Autor:
M Asif A Siddiqui, Keri Wellington
Publikováno v:
Drugs. 65:2139-2146
Palifermin, a recombinant human keratinocyte growth factor (KGF), mimics the actions of endogenous KGF and has shown efficacy in the management of myelotoxic therapy-induced oral mucositis in cancer patients. In a randomised, double-blind trial in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1ede580e34834fa702ea62eea32d18c
https://doi.org/10.2165/00003495-200565150-00008
https://doi.org/10.2165/00003495-200565150-00008
Autor:
Adam McGechan, Keri Wellington
Publikováno v:
CNS Drugs. 19:1057-1065
▲ Ramelteon, approved in the US for the treatment of insomnia characterised by difficulty with sleep onset, is a highly selective agonist for the melatonin MT1/MT2 receptors, which are believed to mediate the circadian rhythm in mammals. ▲ Ramelt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b04b32f162e65fb3840154344f45bf93
https://doi.org/10.2165/00023210-200519120-00007
https://doi.org/10.2165/00023210-200519120-00007
Autor:
Keri Wellington, Monique P Curran
Publikováno v:
Treatments in Respiratory Medicine. 4:149-152
Cefditoren pivoxil (Spectracef®, Meiact®) is a third-generation oral cephalosporin with a broad spectrum of activity against pathogens, including both Gram-positive and -negative bacteria, and is stable to hydrolysis by many common β-lactamases. C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d52e653c6307eb63044124aa740a6d59
https://doi.org/10.2165/00151829-200504020-00012
https://doi.org/10.2165/00151829-200504020-00012
Publikováno v:
Treatments in Respiratory Medicine. 4:139-145
Lucinactant, formerly known as KL(4) surfactant, is a novel synthetic lung surfactant containing phospholipids and an engineered peptide, sinapultide, which is designed to mimic the actions of human surfactant protein B. It has been developed for use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c82b2ebde2e439218afcfe5d3323ba24
https://doi.org/10.2165/00151829-200504020-00008
https://doi.org/10.2165/00151829-200504020-00008
Autor:
Keri Wellington, Vicki Oldfield
Publikováno v:
American Journal of Cancer. 4:337-344
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0087220a74c46af0fcb1e2edb55ac656
https://doi.org/10.2165/00024669-200504050-00011
https://doi.org/10.2165/00024669-200504050-00011
Autor:
M Asif A Siddiqui, Keri Wellington
Publikováno v:
CNS Drugs. 19:55-61
Intramuscular interferon-beta-1a, a recombinant interferon-beta approved in the US for the treatment of relapsing forms of multiple sclerosis (MS), has also been evaluated in the treatment of patients with a first clinical demyelinating episode and b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::425a5bb602f7549539778a90e76325d2
https://doi.org/10.2165/00023210-200519010-00005
https://doi.org/10.2165/00023210-200519010-00005
Autor:
Gillian M. Keating, Keri Wellington
Publikováno v:
Drugs. 64:1375-1381
A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7478b5669d59b5edce94d468cc6e6b31
https://doi.org/10.2165/00003495-200464120-00008
https://doi.org/10.2165/00003495-200464120-00008